Evidence map›Paper›PMID 40230706›Full record

ArticleBlood science (Baltimore, Md.)2025

Superiority of allo-SCT to auto-SCT in high-risk T-cell lymphoblastic lymphoma/leukemia patients with aaIPI ≥3: insights from a retrospective, multicenter analysis.

Xiaodan Luo, Zhiping Fan, Runhui Zheng, Fen Huang, Na Xu, Pengfei Qin, Jingren Lin, Chunyan Wang, Huiqiang Huang, Huo Tan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood science (Baltimore, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaodan LuoHematology Department, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhiping FanDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Runhui ZhengHematology Department, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Fen HuangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Na XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Pengfei QinDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jingren LinDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Chunyan WangDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Huiqiang HuangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China/Cancer Center, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
Huo TanHematology Department, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Qifa LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High recurrence is a major challenge in treating T-lymphoblastic lymphoma (T-LBL). Allogeneic (allo-) or autologous (auto-) stem cell transplantation (SCT) is recommended to reduce relapse, though the optimal choice remains unclear. This study retrospectively analyzed outcomes in T-LBL patients undergoing SCT, with 44 patients receiving allo-SCT and 25 receiving auto-SCT. After a median follow-up of 115 months, the 5-year cumulative incidence of relapse (CIR) was 30.4% overall, 28.7% for allo-SCT, and 37.7% for auto-SCT (

Indexed as

AllogenicGvHDLymphomaT-cellTransplantation

Identifiers

PMID40230706
PMCPMC11995990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.